According to Teva, its worldwide sales of respiratory drugs, including the Pro-Air albuterol and QVAR beclomethasone inhalers, were down 3% from 2009, to $875 million. Of that amount, $556 million is attributable to sales in the US, where ProAir has a nearly 50% market share and QVAR is the 2nd place inhaled ICS. Read the company’s press release
